Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-07-2009 | Original Article

Bone marrow dosimetry in peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate

Authors: Flavio Forrer, Eric P. Krenning, Peter P. Kooij, Bert F. Bernard, Mark Konijnenberg, Willem H. Bakker, Jaap J. M. Teunissen, Marion de Jong, Kirsten van Lom, Wouter W. de Herder, Dik J. Kwekkeboom

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2009

Abstract

Purpose

Adequate dosimetry is mandatory for effective and safe peptide receptor radionuclide therapy (PRRT). Besides the kidneys, the bone marrow is a potentially dose-limiting organ. The radiation dose to the bone marrow is usually calculated according to the MIRD scheme, where the accumulated activity in the bone marrow is calculated from the accumulated radioactivity of the radiopharmaceutical in the blood. This may underestimate the absorbed dose since stem cells express somatostatin receptors. We verified the blood-based method by comparing the activity in the blood with the radioactivity in bone marrow aspirates. Also, we evaluated the absorbed cross-dose from the source organs (liver, spleen, kidneys and blood), tumours and the so-called “remainder of the body” to the bone marrow.

Methods

Bone marrow aspirates were drawn in 15 patients after treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate. Radioactivity in the bone marrow was compared with radioactivity in the blood drawn simultaneously. The nucleated cell fraction was isolated from the bone marrow aspirate and radioactivity was measured. The absorbed dose to the bone marrow was calculated. The results were correlated to the change in platelet counts 6 weeks after treatment.

Results

A strong linear correlation and high agreement between the measured radioactivities in the bone marrow aspirates and in the blood was found (r=0.914, p<0.001). No correlation between the calculated absorbed dose in the bone marrow and the change in platelets was found. There was a considerable contribution from other organs and the remainder of the body to the bone marrow absorbed dose.

Conclusion

(1) After PRRT with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate, the radioactivity concentration in the bone marrow is identical to that in the blood; (2) There is no significant binding of the radiopharmaceutical to bone marrow precursor stem cells; (3) The contribution of the cross dose from source organs and tumours to the bone marrow dose is significant; and (4) There is considerable variation in bone marrow absorbed dose between patients. These findings imply that for individual dose optimization, individual calculation of the bone marrow absorbed dose is necessary.

Waldherr C, Pless M, Maecke H, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43:610–16.PubMed

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med 2003;30:417–22.

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439–47.PubMedCrossRef

Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005;46:1310–16.PubMed

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S–66S.PubMed

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA(0),Tyr(3)]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–62.PubMedCrossRef

Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, et al. 90Y-DOTA-D-Phe(1)-Try(3)-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393–8.PubMedCrossRef

Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37:847–51.PubMedCrossRef

Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46(Suppl 1):83S–91S.PubMed

10.

Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487) – a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510–8.PubMed

11.

Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46(Suppl 1):99S–106S.PubMed

12.

Konijnenberg MW, Bijster M, Krenning EP, De Jong M. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. J Nucl Med 2004;45:1260–9.PubMed

13.

Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006;33:1346–51.PubMedCrossRef

14.

Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110–22.PubMedCrossRef

15.

Kwekkeboom DJ, Bakker WH, Teunissen JJM, Kooij PP, Krenning EP. Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: interim results (abstract). Eur J Nucl Med Mol Imaging 2003;30(Suppl 2):S231.

16.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabelled somatostatin analogue [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.CrossRef

17.

ICRP. Publication 41: nonstochastic effects of ionizing radiation. Pergamon Press, Oxford, 1984.

18.

Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, et al. Molecular and cellular biology of moderate-dose (1–10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17–18, 2001. Radiat Res 2003;159:812–34.PubMedCrossRef

19.

Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR Am J Roentgenol 1962;87:171–82.

20.

Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003;44:451–6.PubMed

21.

Siegel JA, Wessels BW, Watson EE, Stabin MG, Vriesendorp HM, Bradley EW, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharm 1990;3:213–33.

22.

Wessels BW, Bolch WE, Bouchet LG, Breitz HB, DeNardo GL, Meredith RF, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 2004;45:1725–33.PubMed

23.

Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 1999;26:877–86.PubMedCrossRef

24.

Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689–94.PubMed

25.

Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O’Donnell RT, et al. Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. J Nucl Med 2005;46:1034–41.PubMed

26.

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.PubMedCrossRef

27.

Lichtenauer-Kaligis EG, Dalm VA, Oomen SP, Mooij DM, van Hagen PM, Lamberts SW, et al. Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. Eur J Endocrinol 2004;150:565–77.PubMedCrossRef

28.

Oomen SP, van Hennik PB, Antonissen C, Lichtenauer-Kaligis EG, Hofland LJ, Lamberts SW, et al. Somatostatin is a selective chemoattractant for primitive (CD34(+)) hematopoietic progenitor cells. Exp Hematol 2002;30:116–25.PubMedCrossRef

29.

Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):92S–98S.PubMed

30.

Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2005;32:458–69.PubMedCrossRef

31.

Stabin MG, Siegel JA, Sparks RB, Eckerman KF, Breitz HB. Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method. J Nucl Med 2001;42:492–8.PubMed

32.

Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42:1713–21.PubMed

33.

Lim SM, DeNardo GL, DeNardo DA, Shen S, Yuan A, O’Donnell RT, et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med 1997;38:1374–78.PubMed

34.

Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 2005;46:850–58.PubMed

35.

Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med 1999;40:1609–616.PubMed

36.

Blumenthal RD, Lew W, Juweid M, Alisauskas R, Ying Z, Goldenberg DM. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer 2000;88:333–43.PubMedCrossRef

37.

Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 2003;44(1):67–76.PubMed

38.

Sgouros G. Dosimetry of internal emitters. J Nucl Med 2005;46(Suppl 1):18S–27S.PubMed

39.

Walrand S, Barone R, Jamar F, De Camps J, Krenning EP, Valkema R, et al. Red marrow 90Y-OctreoTher dosimetry estimated using 86Y-OctreoTher PET and biological correlates (abstract). Eur J Nucl Med Mol Imaging 2002;29(Suppl 1):301S.

40.

Pentlow KS, Finn RD, Larson SM, Erdi YE, Beattie BJ, Humm JL. Quantitative imaging of yttrium-86 with PET. The occurrence and correction of anomalous apparent activity in high density regions. Clin Positron Imaging. 2000;3:85–90.PubMedCrossRef

41.

Buchholz HG, Herzog H, Forster GJ, Reber H, Nickel O, Rosch F, et al. PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction. Eur J Nucl Med Mol Imaging 2003;30:716–20.PubMed

42.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRef

43.

Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA(0)Tyr(3)]octreotate: comparison with [111In-DTPA(0)]octreotide in patients. Eur J Nucl Med 2001;28:1319–25.PubMedCrossRef

Title: Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Authors: Flavio Forrer
Eric P. Krenning
Peter P. Kooij
Bert F. Bernard
Mark Konijnenberg
Willem H. Bakker
Jaap J. M. Teunissen
Marion de Jong
Kirsten van Lom
Wouter W. de Herder
Dik J. Kwekkeboom
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1072-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bone marrow dosimetry in peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2009

Improved quantification in single-pinhole and multiple-pinhole SPECT using micro-CT information

Intraoperative radioguidance with a portable gamma camera: a novel technique for laparoscopic sentinel node localisation in urological malignancies

Steroid hormones affect binding of the sigma ligand 11C-SA4503 in tumour cells and tumour-bearing rats

Attenuation correction for lung SPECT: evidence of need and validation of an attenuation map derived from the emission data

Positron emission tomography in patients suffering from HIV-1 infection

FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours